Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zilxi (FMX-103) in papulopustular rosacea
NCT02601963Phase 2Completed
- Sponsor
- Vyne Therapeutics
- Start
- Sep 2015
- Primary completion
- Aug 2016
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zilxi in papulopustular rosacea, sponsored by Vyne Therapeutics. Started Sep 2015; status: completed.
02
Drugs
zilxi
03
Conditions
papulopustular rosacea
Beyond the preview
Go deeper on NCT02601963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02601963.